Ondine food-safe photodisinfection update
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Ondine food-safe photodisinfection update
Canadian life sciences company, Ondine Biomedical, has concluded the first development phase of a new food-safe photodisinfection technology for Canada's meat packing industry. The findings which will be presented at a webinar on Wednesday 12 April, 2023 will report on identifying and screening potential food-safe photosensitizers for efficacy against bacterial biofilms common in food processing.
In December 2022 Ondine was awarded nearly $735,000 to undertake this research, which was funded in part by the Government of Canada under the Canadian Agricultural Partnership's AgriScience Program, a federal, provincial, territorial initiative.The AgriScience Program aims to accelerate the pace of innovation by providing funding and support for pre-commercial science activities and cutting-edge research that benefits consumers and the agriculture and agri-food sector.
The food-processing industry has a need for the development of technologies to reduce the incidence of food-borne pathogens including bacteria, fungi, viruses, and protozoa. Eradicating these invasive microbes will help protect the $9.4 billion (2021) Canadian meat export industry, as well enhance the lives and welfare of consumers by reducing the incidence of food-borne illnesses.
Ondine is the world leader in the development of photodisinfection technology, and has already proven the safety and effectiveness of the technology at hospitals across Canada where it is used to decolonize the nose prior to surgery to prevent surgical site infections ( SSIs) - Vancouver General Hospital has reported reducing SSIs in patients undergoing major surgery by over 50%.
Webinar: "Photodisinfection for Food Safety"
Timing: Wednesday 12 April, 2023 at 12:00pm EST / 5:00pm BST
Registration: https://go.marketing.ondinebio.com/WebRegistration
Panelists:
· Dr. Richard Rusk (DVM, MD, CCFP, MPH, DipZBPV, FRSPH), Prevention Medicine Specialist and former Manitoba Medical Officer of Health
· Dr. Nicolas Loebel, Ondine Biomedical President and Chief Technology Officer
· Dr. Joseph Ross, Senior Scientist at Chinook Contract Research
**ENDS**
|
Ondine Biomedical Inc. |
|
|
Angelika Vance, Corporate Communications |
+001 (604) 838 2702 |
|
|
|
|
Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
|
Aubrey Powell, Asha Chotai, Sam Butcher |
+44 (0)20 7496 3000 |
|
|
|
|
RBC Capital Markets (Joint Broker) |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0)20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy, Amanda Bernard |
+44 (0)77 1000 5910 |
Microbial foodborne disease
Foodborne illnesses are a major public health concern due to the high risk of microbial contamination of food. In 2010, more than 580 million illnesses and 351,000 deaths worldwide were associated with food contaminated by enteric pathogens according to a World Health Organization (WHO) estimate. Meat and meat-based products are particularly prone to contamination, accounting for more than 16% of total foodborne outbreaks in Europe in 2016.
Source: Int. J. Environ. Res. Public Health 2020, 17, 688; doi:10.3390/ijerph17030688
About photodisinfection
Ondine's photodisinfection is a patented technology using a proprietary photosensitizer (non-antibiotic, light-activated solution) to destroy pathogens. When illuminated with a specific wavelength of light, the photosensitizer is activated, causing an oxidative burst that is lethal to all types of pathogens.
Ondine's nasal photodisinfection system has a CE mark and is approved in Canada and several other countries under the name Steriwave™. It has been used in Canada for over ten years, with no serious adverse events reported. In the US, it is currently undergoing clinical trials for regulatory approval.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund